Zanubrutinib monotherapy (continuous)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ZANUBRUTINIB |
|---|
| ID | REG-ZANUBRUTINIB-WM |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
ASPEN trial demonstrated superior hematologic + safety profile vs ibrutinib in MYD88-mutated WM. Preferred BTKi for WM 1L. CXCR4 WHIM-mutated subset has reduced depth of response — consider chemo combination.
Used By
Indication
IND-WM-1L-BTKI- IND-WM-1L-BTKI